Vivek K. Vyas

1.8k total citations
86 papers, 1.4k citations indexed

About

Vivek K. Vyas is a scholar working on Molecular Biology, Computational Theory and Mathematics and Organic Chemistry. According to data from OpenAlex, Vivek K. Vyas has authored 86 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Molecular Biology, 28 papers in Computational Theory and Mathematics and 25 papers in Organic Chemistry. Recurrent topics in Vivek K. Vyas's work include Computational Drug Discovery Methods (28 papers), Synthesis and biological activity (22 papers) and Biochemical and Molecular Research (19 papers). Vivek K. Vyas is often cited by papers focused on Computational Drug Discovery Methods (28 papers), Synthesis and biological activity (22 papers) and Biochemical and Molecular Research (19 papers). Vivek K. Vyas collaborates with scholars based in India, Italy and Japan. Vivek K. Vyas's co-authors include Manjunath Ghate, Chetan Chintha, Hardik Bhatt, Palak Patel, Ashutosh Goel, Bhavesh C. Variya, Bhagawati Saxena, Pavan Srivastava, Palak K. Parikh and Milee Agarwal and has published in prestigious journals such as SHILAP Revista de lepidopterología, RSC Advances and International Journal of Biological Macromolecules.

In The Last Decade

Vivek K. Vyas

79 papers receiving 1.3k citations

Peers

Countries citing papers authored by Vivek K. Vyas

Since Specialization

Citations

This map shows the geographic impact of Vivek K. Vyas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek K. Vyas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek K. Vyas more than expected).

Fields of papers citing papers by Vivek K. Vyas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivek K. Vyas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek K. Vyas. The network helps show where Vivek K. Vyas may publish in the future.

Co-authorship network of co-authors of Vivek K. Vyas

This figure shows the co-authorship network connecting the top 25 collaborators of Vivek K. Vyas. A scholar is included among the top collaborators of Vivek K. Vyas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivek K. Vyas. Vivek K. Vyas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure-guided computational design of novel polycyclic aromatic compounds as telomerase inhibitors for the treatment of cancer 2025 ·Network Modeling Analysis in Health Informatics and Bioinformatics ·(unknown), Bhumika Patel, Vivek K. Vyas, (unknown), Saumya Patel, Hardik Bhatt	0
2	A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD) 2024 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), Sunil Kumar, Naveen Choudhary, Vivek K. Vyas	4
3	A comprehensive review of synthetic strategies and SAR studies for the discovery of PfDHODH inhibitors as antimalarial agents. Part 1: triazolopyrimidine, isoxazolopyrimidine and pyrrole-based (DSM) compounds 2024 ·Bioorganic Chemistry ·(unknown), (unknown), Giulio Poli, Tiziano Tuccinardi, Marco L. Lolli, Vivek K. Vyas	6
4	A comprehensive review of synthetic strategies and SAR studies for the discovery of PfDHODH inhibitors as antimalarial agents. Part 2: Non-DSM compounds 2024 ·Bioorganic Chemistry ·(unknown), Marco L. Lolli, Vivek K. Vyas	1
5	Discovery of Thiadiazoles as Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors by Combined Structure‐Based Modelling Methods 2024 ·ChemistrySelect ·(unknown), (unknown), Vipin Kumar, Vivek K. Vyas	1
6	Evolution of Telomerase Inhibitors: A Review on Key Patents from 2015 to 2023 2024 ·ChemistrySelect ·(unknown), (unknown), Bhumika Patel, Vivek K. Vyas, Hardik Bhatt	4
7	Design, synthesis and pharmacological evaluation of novel thiazole derivatives as c-Met kinase inhibitors and anticancer agents 2024 ·Journal of Molecular Structure ·(unknown), (unknown), Vivek K. Vyas, Tejas M. Dhameliya, Palak K. Parikh, Manjunath Ghate	4
8	3D-QSAR assisted design, synthesis and pharmacological evaluation of novel substituted benzamides as procaspase-3 activators and anticancer agents 2023 ·Journal of Molecular Structure ·(unknown), (unknown), (unknown), Manjunath Ghate, Vivek K. Vyas	5
9	Design of 2-amino-6-methyl-pyrimidine benzoic acids as ATP competitive casein kinase-2 (CK2) inhibitors using structure- and fragment-based design, docking and molecular dynamic simulation studies 2023 ·SAR and QSAR in environmental research ·Saumya Patel, (unknown), Sivakumar Prasanth Kumar, Vivek K. Vyas, Manjunath Ghate	3
10	Structure-Guided Discovery of Adenosine Triphosphate-Competitive Casein Kinase 2 Inhibitors 2023 ·Future Medicinal Chemistry ·(unknown), Vivek K. Vyas, (unknown), Manjunath Ghate	1
11	Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review 2022 ·Bioorganic & Medicinal Chemistry ·(unknown), Sunil Kumar, Vivek K. Vyas, (unknown), (unknown), Ruchi Malik	29
12	Therapeutic potential of 4-substituted coumarins: A conspectus 2022 ·SHILAP Revista de lepidopterología ·(unknown), Vivek K. Vyas, (unknown), Manjunath Ghate	20
13	Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders 2021 ·European Journal of Medicinal Chemistry ·(unknown), Palak K. Parikh, Vivek K. Vyas, Manjunath Ghate	28
14	Pharmacophore-based identification and in vitro validation of apoptosis inducers as anticancer agents 2020 ·SAR and QSAR in environmental research ·Vivek K. Vyas, (unknown), (unknown), (unknown), Manjunath Ghate	4
15	Neuroprotective Effects of Ethyl Pyruvate against Aluminum Chloride-Induced Alzheimer’s Disease in Rats via Inhibiting Toll-Like Receptor 4 2020 ·Journal of Molecular Neuroscience ·(unknown), Milee Agarwal, Vivek K. Vyas, Bhagawati Saxena	38
16	3D QSAR-based design and liquid phase combinatorial synthesis of 1,2-disubstituted benzimidazole-5-carboxylic acid and 3-substituted-5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one derivatives as anti-mycobacterial agents 2019 ·MedChemComm ·(unknown), Vivek K. Vyas, (unknown), (unknown), (unknown), Saqib Kidwai, Ramandeep Singh, Manjunath Ghate	7
17	Synthesis of 2-,4,-6-, and/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design 2019 ·Bioorganic & Medicinal Chemistry Letters ·Vivek K. Vyas, (unknown), (unknown), (unknown), (unknown), Palak Patel, Manjunath Ghate	18
18	Combined in silico approaches for the identification of novel inhibitors of human islet amyloid polypeptide (hIAPP) fibrillation 2017 ·Journal of Molecular Graphics and Modelling ·Palak Patel, (unknown), Vivek K. Vyas, Dhaval Patel, Mili Das	21
19	3D QSAR Studies on Substituted Benzimidazole Derivatives as Angiotensin II-AT<sub>1</sub> Receptor Antagonist 2013 ·Current Computer - Aided Drug Design ·Vivek K. Vyas, Manjunath Ghate, Chetan Chintha, Paresh K. Patel	3
20	A Comprehensive Review on Withania somnifera Dunal 2011 ·Journal of Natural Remedies ·Vivek K. Vyas, Pratik Bhandari, (unknown)	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact